Loading...

We've got a brand new version of Simply Wall St! Try it out

Bora Pharmaceuticals

GTSM:6472
Snowflake Description

Exceptional growth potential with flawless balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6472
GTSM
NT$6B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Bora Pharmaceuticals Co., LTD. engages in the research, development, production, marketing, sale, and distribution of pharmaceutical products. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
6472 Share Price and Events
7 Day Returns
1.9%
GTSM:6472
-1.7%
TW Pharmaceuticals
-0.5%
TW Market
1 Year Returns
75.5%
GTSM:6472
16%
TW Pharmaceuticals
17.7%
TW Market
6472 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bora Pharmaceuticals (6472) 1.9% -1.8% 3.2% 75.5% 201.4% 79.1%
TW Pharmaceuticals -1.7% 3.4% 3.5% 16% -10.7% -23.2%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 6472 outperformed the Pharmaceuticals industry which returned 16% over the past year.
  • 6472 outperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
6472
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Bora Pharmaceuticals's competitors could be found in our database.

Value

 Is Bora Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Bora Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Bora Pharmaceuticals.

GTSM:6472 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.7%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:6472
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.687 (1 + (1- 20%) (13.24%))
0.839
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.84
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.839 * 5.96%)
7.73%

Discounted Cash Flow Calculation for GTSM:6472 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Bora Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

GTSM:6472 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 7.73%)
2020 563.00 Analyst x1 522.59
2021 749.00 Analyst x1 645.34
2022 891.98 Est @ 19.09% 713.37
2023 1,018.48 Est @ 14.18% 756.07
2024 1,127.93 Est @ 10.75% 777.22
2025 1,222.01 Est @ 8.34% 781.61
2026 1,303.37 Est @ 6.66% 773.81
2027 1,374.79 Est @ 5.48% 757.63
2028 1,438.78 Est @ 4.65% 735.98
2029 1,497.45 Est @ 4.08% 711.01
Present value of next 10 years cash flows NT$7,174.00
GTSM:6472 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$1,497.45 × (1 + 2.73%) ÷ (7.73% – 2.73%)
NT$30,749.77
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$30,749.77 ÷ (1 + 7.73%)10
NT$14,600.41
GTSM:6472 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$7,174.00 + NT$14,600.41
NT$21,774.41
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$21,774.41 / 38.41
NT$566.91
GTSM:6472 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$566.91
Current discount Discount to share price of NT$160.00
= -1 x (NT$160.00 - NT$566.91) / NT$566.91
71.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Bora Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is NT$160 vs Future cash flow value of NT$566.91
Current Discount Checks
For Bora Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Bora Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Bora Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bora Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bora Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6472 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$9.28
GTSM:6472 Share Price ** GTSM (2019-11-18) in TWD NT$160
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 22.23x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bora Pharmaceuticals.

GTSM:6472 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6472 Share Price ÷ EPS (both in TWD)

= 160 ÷ 9.28

17.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bora Pharmaceuticals is good value based on earnings compared to the TW Pharmaceuticals industry average.
  • Bora Pharmaceuticals is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Bora Pharmaceuticals's expected growth come at a high price?
Raw Data
GTSM:6472 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 17.24x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
34.6%per year
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.89x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

GTSM:6472 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 17.24x ÷ 34.6%

0.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bora Pharmaceuticals is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Bora Pharmaceuticals's assets?
Raw Data
GTSM:6472 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$41.20
GTSM:6472 Share Price * GTSM (2019-11-18) in TWD NT$160
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.17x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:6472 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6472 Share Price ÷ Book Value per Share (both in TWD)

= 160 ÷ 41.20

3.88x

* Primary Listing of Bora Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bora Pharmaceuticals is overvalued based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess Bora Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Bora Pharmaceuticals has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Bora Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bora Pharmaceuticals expected to grow at an attractive rate?
  • Bora Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Bora Pharmaceuticals's earnings growth is expected to exceed the Taiwan, Province of China market average.
  • Bora Pharmaceuticals's revenue growth is expected to exceed the Taiwan, Province of China market average.
Annual Growth Rates Comparison
Raw Data
GTSM:6472 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:6472 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 34.6%
GTSM:6472 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 25.8%
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 20.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6472 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6472 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 2,653 765 724 1
2020-12-31 1,922 534 523 2
2019-12-31 1,543 501 354 1
2019-11-18
GTSM:6472 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 1,517 449 355
2019-06-30 1,492 373 283
2019-03-31 1,515 311 267
2018-12-31 1,372 167 443
2018-09-30 1,107 -40 558
2018-06-30 846 -218 330
2018-03-31 525 -263 274
2017-12-31 358 20 14
2017-09-30 323 2 17
2017-06-30 297 22 22
2017-03-31 291 5 24
2016-12-31 283 -18 25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Bora Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Bora Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6472 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Bora Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6472 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 18.40 18.40 18.40 1.00
2020-12-31 13.30 13.30 13.30 1.00
2019-12-31 10.44 10.44 10.44 1.00
2019-11-18
GTSM:6472 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 9.28
2019-06-30 7.50
2019-03-31 7.22
2018-12-31 12.44
2018-09-30 16.38
2018-06-30 9.73
2018-03-31 8.20
2017-12-31 0.43
2017-09-30 0.53
2017-06-30 0.70
2017-03-31 0.80
2016-12-31 0.81

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Bora Pharmaceuticals is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Bora Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bora Pharmaceuticals has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Bora Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bora Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bora Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • Bora Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Bora Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the TW Pharmaceuticals industry average.
Earnings and Revenue History
Bora Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bora Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6472 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 1,517.35 355.48 217.43 37.76
2019-06-30 1,491.90 283.37 236.19 40.71
2019-03-31 1,514.81 266.62 227.23 40.62
2018-12-31 1,372.43 442.84 219.74 38.32
2018-09-30 1,107.02 557.99 201.32 35.67
2018-06-30 846.19 330.29 141.04 28.18
2018-03-31 525.41 274.50 115.95 23.01
2017-12-31 357.82 14.02 87.28 20.13
2017-09-30 323.09 17.04 81.15 18.63
2017-06-30 297.26 21.61 74.32 17.57
2017-03-31 291.21 24.07 72.72 17.58
2016-12-31 283.26 24.57 70.51 17.91
2016-09-30 273.41 22.50 68.19 18.48
2016-06-30 259.96 18.00 68.80 17.86
2016-03-31 246.73 25.80 66.58 17.38
2015-12-31 237.65 33.66 64.93 17.05
2015-09-30 235.51 29.97 65.44 13.20
2015-06-30 233.73 28.42 67.89 12.05
2015-03-31 225.84 22.51 65.12 10.32
2014-12-31 217.96 16.60 62.34 8.60
2014-09-30 182.00 15.65 53.88 8.82
2014-06-30 153.50 16.21 44.40 7.98
2014-03-31 123.18 10.05 40.87 5.58
2013-12-31 92.86 3.88 37.34 3.19
2012-12-31 46.33 -16.73 34.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Bora Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Bora Pharmaceuticals used its assets more efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • Bora Pharmaceuticals has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Bora Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bora Pharmaceuticals has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Bora Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bora Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bora Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bora Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bora Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bora Pharmaceuticals Company Filings, last reported 1 month ago.

GTSM:6472 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 1,593.90 509.31 584.78
2019-06-30 1,412.05 529.28 399.05
2019-03-31 1,408.64 538.04 366.79
2018-12-31 1,320.88 556.43 527.60
2018-09-30 1,223.87 605.66 378.33
2018-06-30 735.70 915.51 312.32
2018-03-31 672.68 965.10 284.59
2017-12-31 632.20 198.94 247.93
2017-09-30 633.54 203.19 248.38
2017-06-30 641.98 207.42 308.19
2017-03-31 476.54 231.63 146.31
2016-12-31 473.54 215.82 118.54
2016-09-30 464.17 240.00 150.73
2016-06-30 457.48 240.00 176.36
2016-03-31 468.27 325.00 211.32
2015-12-31 468.27 325.00 211.32
2015-09-30 460.96 310.00 213.87
2015-06-30 468.53 300.00 249.72
2015-03-31 445.84 482.00 138.02
2014-12-31 445.84 482.00 138.02
2014-09-30
2014-06-30 440.11 220.00 97.19
2014-03-31 317.24 220.00 89.59
2013-12-31 317.24 220.00 89.59
2012-12-31 21.60 0.00 11.83
  • Bora Pharmaceuticals's level of debt (32%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (79.6% vs 32% today).
  • Debt is well covered by operating cash flow (88.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 31.1x coverage).
X
Financial health checks
We assess Bora Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bora Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Bora Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.44%
Current annual income from Bora Pharmaceuticals dividends. Estimated to be 2.26% next year.
If you bought NT$2,000 of Bora Pharmaceuticals shares you are expected to receive NT$29 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Bora Pharmaceuticals's pays a lower dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (2.57%).
  • Bora Pharmaceuticals's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (5.93%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6472 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:6472 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 4.91 1.00
2020-12-31 3.55 1.00
2019-12-31 2.40 1.00
2019-11-18
GTSM:6472 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2019-03-29 2.308 1.769
2019-03-26 2.308 2.138
2018-03-30 0.385 0.424
2017-02-23 0.615 1.990
2016-04-26 0.444 0.923
2015-08-24 0.370 0.651
2015-04-29 0.370 0.425
2015-04-28 0.370 0.424

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bora Pharmaceuticals has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Dividend payments have increased, but Bora Pharmaceuticals only paid a dividend in the past 5 years.
Current Payout to shareholders
What portion of Bora Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (4x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.7x coverage).
X
Income/ dividend checks
We assess Bora Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bora Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bora Pharmaceuticals has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Bora Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bobby Sheng
CEO Bio

Mr. Bobby Sheng is the Principle Founder, the Chairman and Chief Executive Officer of Bora Corporation and Bora Pharmaceuticals Inc. (alternate name, Bora Pharmaceuticals Co., Ltd.). Mr. Sheng is Founder of Earth 88 and serves as its Chief Executive Officer. He has one of the most impressive track records for identifying specific needs in the market and creating high quality products for the Asian market. He has experience in Pharmaceuticals, consumer products and media gives him a perspective on the market. He successfully launched many prestigious brands such as Hard Candy, PeterThomasRoth, Osmotics, Tweezerman and Kiehl’s in Taiwan and in 1997. His Key Achievements include: At Hoan Pharma, he successfully launched multiple pharmaceutical lines, including Lexapro, the marketing leading Anti-depressant in Taiwan. After investing in many successful years in the core pharmaceutical business, he ventured out to establish his own group of companies that focuses on bringing products and services from the Western Cultures to Taiwan and the rest of Asia. He serves as a Director of O-Bank Co., Ltd(also known as Industrial Bank of Taiwan). He was named one of Asia’s Top Businessmen by the International Luxury Brands group LVMH. He studied from University of California, Berkeley in the year 1990-1994.

CEO Compensation
  • Insufficient data for Bobby to compare compensation growth.
  • Insufficient data for Bobby to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team

Bobby Sheng

TITLE
Chairman & CEO

David Tseng

TITLE
Executive Director of Business Development

Changan Chen

TITLE
Consultant
Board of Directors

Bobby Sheng

TITLE
Chairman & CEO

Guan Bai Chen

TITLE
Director

Shang Hong Shen

TITLE
Director

Xiao Tai He

TITLE
Director

Xin Li

TITLE
Supervisor

Xin Yi Lai

TITLE
Supervisor
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Bora Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bora Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Bora Pharmaceuticals Co., LTD. engages in the research, development, production, marketing, sale, and distribution of pharmaceutical products. The company provides antidepressant, antipsychotic, dementia, sedative, antihypertensive, atherosclerosis, hypoglycemic drugs, antacids, ophthalmic agents, antiparkinsonism agents, antibiotics agents, and osteoarthritis drugs; health supplements, such as BOOST; and skin care products, including Eisai-SAHNE and Eisai-Aloe. It also offers market analysis, registration, regulatory affairs, pricing, GDP warehousing, distribution, and market access, as well as marketing and sales services to multinational pharmaceutical, over-the-counter, and consumer healthcare companies. The company’s sales and distribution network comprises hospitals, clinics, pharmacies, CVS, and specialty channels. It also exports its products to approximately 17 countries worldwide. The company was founded in 2007 and is based in Taipei City, Taiwan.

Details
Name: Bora Pharmaceuticals Co., LTD.
6472
Exchange: GTSM
Founded: 2007
NT$6,145,457,280
38,409,108
Website: http://www.bora-corp.com
Address: Bora Pharmaceuticals Co., LTD.
No. 69, Xing’ai Road,
6th Floor,
Taipei City,
114,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6472 Common Stock Taipei Exchange TW TWD 03. Oct 2014
Number of employees
Current staff
Staff numbers
0
Bora Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 15:40
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/11/13
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.